| The 2016 European Thyroid Association/European Group on Graves' orbitopathy guidelines for the management of Graves' orbitopathy L Bartalena, L Baldeschi, K Boboridis, A Eckstein, GJ Kahaly, C Marcocci, ... European thyroid journal 5 (1), 9-26, 2016 | 1012 | 2016 |
| Consensus statement of the European Group on Graves' orbitopathy (EUGOGO) on management of GO L Bartalena, L Baldeschi, A Dickinson, A Eckstein, P Kendall-Taylor, ... European Journal of Endocrinology 158 (3), 273-285, 2008 | 882 | 2008 |
| Teprotumumab for thyroid-associated ophthalmopathy TJ Smith, GJ Kahaly, DG Ezra, JC Fleming, RA Dailey, RA Tang, ... New England Journal of Medicine 376 (18), 1748-1761, 2017 | 693 | 2017 |
| Consensus statement of the European group on Graves' orbitopathy (EUGOGO) on management of Graves' orbitopathy L Bartalena, L Baldeschi, AJ Dickinson, A Eckstein, P Kendall-Taylor, ... Thyroid 18 (3), 333-346, 2008 | 607 | 2008 |
| Teprotumumab for the treatment of active thyroid eye disease RS Douglas, GJ Kahaly, A Patel, S Sile, EHZ Thompson, R Perdok, ... New England Journal of Medicine 382 (4), 341-352, 2020 | 556 | 2020 |
| Efficacy of B-cell targeted therapy with rituximab in patients with active moderate to severe Graves' orbitopathy: a randomized controlled study M Salvi, G Vannucchi, N Currò, I Campi, D Covelli, D Dazzi, S Simonetta, ... The Journal of Clinical Endocrinology & Metabolism 100 (2), 422-431, 2015 | 426 | 2015 |
| SARS-CoV-2-related atypical thyroiditis I Muller, D Cannavaro, D Dazzi, D Covelli, G Mantovani, A Muscatello, ... The lancet Diabetes & endocrinology 8 (9), 739-741, 2020 | 359 | 2020 |
| Treatment of Graves’ disease and associated ophthalmopathy with the anti-CD20 monoclonal antibody rituximab: an open study M Salvi, G Vannucchi, I Campi, N Curro, D Dazzi, S Simonetta, P Bonara, ... European journal of endocrinology 156 (1), 33-40, 2007 | 333 | 2007 |
| Efficacy and safety of three different cumulative doses of intravenous methylprednisolone for moderate to severe and active Graves' orbitopathy L Bartalena, GE Krassas, WM Wiersinga, C Marcocci, M Salvi, ... The Journal of Clinical Endocrinology & Metabolism 97 (12), 4454-4463, 2012 | 327 | 2012 |
| Multiple changes in thyroid function in patients with chronic active HCV hepatitis treated with recombinant interferon-alpha E Roti, R Minelli, T Giuberti, S Marchelli, C Schianchi, E Gardini, M Salvi, ... The American journal of medicine 101 (5), 482-487, 1996 | 291 | 1996 |
| Serum concentrations of proinflammatory cytokines in Graves' disease: effect of treatment, thyroid function, ophthalmopathy and cigarette smoking M Salvi, M Pedrazzoni, G Girasole, N Giuliani, R Minelli, JR Wall, E Roti European Journal of Endocrinology 143 (2), 197-202, 2000 | 197 | 2000 |
| Efficacy of rituximab treatment for thyroid-associated ophthalmopathy as a result of intraorbital B-cell depletion in one patient unresponsive to steroid immunosuppression M Salvi, G Vannucchi, I Campi, S Rossi, P Bonara, F Sbrozzi, C Guastella, ... European journal of endocrinology 154 (4), 511-517, 2006 | 192 | 2006 |
| Increased serum concentrations of interleukin-6 (IL-6) and soluble IL-6 receptor in patients with Graves' disease M Salvi, G Girasole, M Pedrazzoni, M Passeri, N Giuliani, R Minelli, ... The Journal of Clinical Endocrinology & Metabolism 81 (8), 2976-2979, 1996 | 192 | 1996 |
| European Group on Graves’ Orbitopathy (EUGOGO). The 2016 European Thyroid Association/European Group on Graves’ Orbitopathy Guidelines for the Management of Graves’ Orbitopathy L Bartalena, L Baldeschi, K Boboridis, A Eckstein, GJ Kahaly, C Marcocci, ... Eur Thyroid J 5 (1), 9-26, 2016 | 186 | 2016 |
| Graves’ orbitopathy as a rare disease in Europe: a European Group on Graves’ Orbitopathy (EUGOGO) position statement P Perros, L Hegedüs, L Bartalena, C Marcocci, GJ Kahaly, L Baldeschi, ... Orphanet journal of rare diseases 12, 1-6, 2017 | 182 | 2017 |
| Outcome of orbital decompression for disfiguring proptosis in patients with Graves’ orbitopathy using various surgical procedures MP Mourits, HM Bijl, MA Altea, L Baldeschi, K Boboridis, N Currò, ... British Journal of Ophthalmology 93 (11), 1518-1523, 2009 | 169 | 2009 |
| Mycophenolate plus methylprednisolone versus methylprednisolone alone in active, moderate-to-severe Graves' orbitopathy (MINGO): a randomised, observer-masked, multicentre trial GJ Kahaly, M Riedl, J König, S Pitz, K Ponto, T Diana, E Kampmann, ... The Lancet Diabetes & Endocrinology 6 (4), 287-298, 2018 | 165 | 2018 |
| PREGO (presentation of Graves’ orbitopathy) study: changes in referral patterns to European Group On Graves’ Orbitopathy (EUGOGO) centres over the period from 2000 to 2012 P Perros, M Žarković, C Azzolini, G Ayvaz, L Baldeschi, L Bartalena, ... British Journal of Ophthalmology 99 (11), 1531-1535, 2015 | 131 | 2015 |
| Human orbital tissue and thyroid membranes express a 64 kDa protein which is recognized by autoantibodies in the serum of patients with thyroid‐associated ophthalmopathy M Salvi, A Miller, JR Wall FEBS letters 232 (1), 135-139, 1988 | 129 | 1988 |
| Management of thyroid eye disease: a consensus statement by the American Thyroid Association and the European Thyroid Association HB Burch, P Perros, T Bednarczuk, DS Cooper, PJ Dolman, AM Leung, ... European thyroid journal 11 (6), 2022 | 126 | 2022 |
